CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally.
Share Price & News
How has CASI Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CASI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CASI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: CASI underperformed the US Biotechs industry which returned 24.9% over the past year.
Return vs Market: CASI underperformed the US Market which returned 33.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is CASI Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWei-Wu He Is The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) And They Just Picked Up 10% More Shares
1 month ago | Simply Wall StUpgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
2 months ago | Simply Wall StCASI Pharmaceuticals' (NASDAQ:CASI) Shareholders Are Down 76% On Their Shares
CASI Pharmaceuticals Fundamentals Summary
|CASI fundamental statistics|
Is CASI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CASI income statement (TTM)|
|Cost of Revenue||US$9.12m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.41|
|Net Profit Margin||-236.69%|
How did CASI perform over the long term?See historical performance and comparison
Is CASI Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CASI ($1.42) is trading below our estimate of fair value ($7.96)
Significantly Below Fair Value: CASI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CASI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CASI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CASI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CASI is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (3.2x).
How is CASI Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CASI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CASI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CASI's is expected to become profitable in the next 3 years.
Revenue vs Market: CASI's revenue (54.8% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: CASI's revenue (54.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CASI's Return on Equity is forecast to be high in 3 years time
How has CASI Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CASI is currently unprofitable.
Growing Profit Margin: CASI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CASI is unprofitable, and losses have increased over the past 5 years at a rate of 38.4% per year.
Accelerating Growth: Unable to compare CASI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CASI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: CASI has a negative Return on Equity (-43.58%), as it is currently unprofitable.
How is CASI Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CASI's short term assets ($83.5M) exceed its short term liabilities ($10.0M).
Long Term Liabilities: CASI's short term assets ($83.5M) exceed its long term liabilities ($17.0M).
Debt to Equity History and Analysis
Debt Level: CASI's debt to equity ratio (1.7%) is considered satisfactory.
Reducing Debt: CASI's debt to equity ratio has reduced from 14.7% to 1.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CASI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CASI has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 35.2% each year.
What is CASI Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CASI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CASI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CASI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CASI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CASI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wei-Wu He (56 yo)
Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...
CEO Compensation Analysis
Compensation vs Market: Wei-Wu's total compensation ($USD819.49K) is about average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: Wei-Wu's compensation has been consistent with company performance over the past year.
Experienced Management: CASI's management team is considered experienced (2.4 years average tenure).
Experienced Board: CASI's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CASI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.8%.
CASI Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: CASI Pharmaceuticals, Inc.
- Ticker: CASI
- Exchange: NasdaqCM
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$198.512m
- Shares outstanding: 139.80m
- Website: https://www.casipharmaceuticals.com
Number of Employees
- CASI Pharmaceuticals, Inc.
- 9620 Medical Center Drive
- Suite 300
- United States
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 22:50|
|End of Day Share Price||2021/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.